公开(公告)号：WO2011137877A2

公开(公告)日：2011-11-10

申请号：PCT/CZ2011/000039

申请日：2011-04-21

Applicant: ZENTIVA K.S. ,  SVOBODA, Martin ,  HERT, Jakub ,  BRUSOVA, Hana ,  PILARCIK, Tomas

Inventor： SVOBODA, Martin ,  HERT, Jakub ,  BRUSOVA, Hana ,  PILARCIK, Tomas

IPC: A61K9/20 ,  A61K9/28 ,  A61K31/4725

CPC classification number: A61K9/2054 ,  A61K9/2866 ,  A61K31/4725

Abstract: The present solution relates to a coated tablet, comprising the active ingredient solifenacin succinate and the binder hydroxypropyl methyl cellulose, wherein the tablet comprises solifenacin I in the range of 3 to 10% wt. of the solifenacin base and methocel as the binder in the range of 0.5 to 5% wt., related to the core weight, wherein after 3-month stability tests at the 75% relative humidity and 40 °C an increase of the content of the N-oxide impurity of formula II is lower than 0.1% of the HPLC integrated area. Another solutions consist in a pharmaceutical preparation comprising the coated tablet packed in a blister package and a manufacturing method of the coated tablets, wherein a powder mixture containing the active ingredient and the binder is granulated by addition of water, whereafter the granulate is tabletted, the resulting tablets are coated and packed.

Abstract translation: 本解决方案涉及包含活性成分琥珀酸solifenacin和粘合剂羟丙基甲基纤维素的包衣片，其中片剂包含3-10重量％范围内的索非那新I。 的solifenacin碱和methocel作为粘合剂，与核心重量相关，为0.5〜5重量％，其中在75％相对湿度和40℃下经过3个月的稳定性试验后， 式II的N-氧化物杂质低于HPLC整合面积的0.1％。 另一种解决方案包括药物制剂，其包含包装在泡罩包装中的包衣片剂和包衣片剂的制备方法，其中含有活性成分和粘合剂的粉末混合物通过加入水造粒，然后将颗粒压片， 得到的片剂被包衣和包装。

公开(公告)号：WO2008017278A2

公开(公告)日：2008-02-14

申请号：PCT/CZ2007/000078

申请日：2007-08-09

Applicant: ZENTIVA, A.S. ,  SVOBODA, Martin ,  JAMPILEK, Josef ,  KACIRKOVA, Martina ,  TOMASEK, Vaclav ,  LEHOCKY, Mikulas ,  HEJTMANKOVA, Ludmila ,  VOSATKA, Vaclav

Inventor： SVOBODA, Martin ,  JAMPILEK, Josef ,  KACIRKOVA, Martina ,  TOMASEK, Vaclav ,  LEHOCKY, Mikulas ,  HEJTMANKOVA, Ludmila ,  VOSATKA, Vaclav

IPC: C07C213/10 ,  C07C215/54 ,  A61K31/137

CPC classification number: C07C215/54 ,  C07C213/10

Abstract: A crystalline salt of 2-[(1R)-3-[bis(l-methylethyl)amino]-1-ρhenylρropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, wherein: a) at least 90 % of all crystals are present in a size smaller than 30 μm, b) at least 40 % of crystalline matter are smaller than 250 μm, c) the maximum size of crystals does not exceed 800 μm, d) the salt contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) provides a value lower than 0.1%. The method of its preparation involves at least one crystallization from water. A pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts further contains a filler, a disintegrant and a lubricant, said composition being free of ions of alkaline earth metals.

Abstract translation: （2R，3R）-2,2-二甲基苯胺的2 - [（1R）-3- [双（1-甲基乙基）氨基] -1-苯基丙基] -4-甲基 - 苯酚的晶体盐， 其中：a）全部晶体的至少90％以小于30μm的尺寸存在，b）至少40％的晶体物质小于250μm， c）晶体的最大尺寸不超过800μm，d）盐含有小于0.1重量％的不希望的对映体S-托特罗定酒石酸盐，e）硫酸盐灰分（欧洲药典）的分析测试提供的值低于 0.1％。 其制备方法涉及至少一次从水中结晶。 包含托特罗定或其药学上可接受的盐的药物组合物还含有填充剂，崩解剂和润滑剂，所述组合物不含碱土金属离子。

公开(公告)号：WO2011137877A3

公开(公告)日：2012-05-18

申请号：PCT/CZ2011000039

申请日：2011-04-21

Applicant: ZENTIVA K S ,  SVOBODA MARTIN ,  HERT JAKUB ,  BRUSOVA HANA ,  PILARCIK TOMAS

Inventor： SVOBODA MARTIN ,  HERT JAKUB ,  BRUSOVA HANA ,  PILARCIK TOMAS

IPC: A61K9/20 ,  A61K9/28 ,  A61K31/4725

CPC classification number: A61K9/2054 ,  A61K9/2866 ,  A61K31/4725

Abstract: The present solution relates to a coated tablet, comprising the active ingredient solifenacin succinate and the binder hydroxypropyl methyl cellulose, wherein the tablet comprises solifenacin I in the range of 3 to 10% wt. of the solifenacin base and methocel as the binder in the range of 0.5 to 5% wt., related to the core weight, wherein after 3-month stability tests at the 75% relative humidity and 40 °C an increase of the content of the N-oxide impurity of formula II is lower than 0.1% of the HPLC integrated area. Another solutions consist in a pharmaceutical preparation comprising the coated tablet packed in a blister package and a manufacturing method of the coated tablets, wherein a powder mixture containing the active ingredient and the binder is granulated by addition of water, whereafter the granulate is tabletted, the resulting tablets are coated and packed.

Abstract translation: 本解决方案涉及包含活性成分琥珀酸solifenacin和粘合剂羟丙基甲基纤维素的包衣片剂，其中片剂包含3-10重量％范围内的solifenacin I。 的solifenacin碱和methocel作为粘合剂，与核心重量有关，其中在75％相对湿度和40℃下经过3个月的稳定性试验后，其含量的增加 式II的N-氧化物杂质低于HPLC整合面积的0.1％。 另一种解决方案包括药物制剂，其包含包装在泡罩包装中的包衣片剂和包衣片剂的制备方法，其中含有活性成分和粘合剂的粉末混合物通过加入水造粒，此后将颗粒压片， 得到的片剂被包衣和包装。

公开(公告)号：WO2005011638A3

公开(公告)日：2005-02-10

申请号：PCT/CZ2004/000045

申请日：2004-08-05

Applicant: ZENTIVA, A. S. ,  SEBEK, Pavel ,  PROKOPOVA, Alena ,  SVOBODA, Eduard ,  RADL, Stanislav ,  STACH, Jan ,  SVOBODA, Martin ,  KOVACIK, Andrej ,  DANKO, Adrian ,  PETRO, Roman ,  STRIZINEC, Miroslav

Inventor： SEBEK, Pavel ,  PROKOPOVA, Alena ,  SVOBODA, Eduard ,  RADL, Stanislav ,  STACH, Jan ,  SVOBODA, Martin ,  KOVACIK, Andrej ,  DANKO, Adrian ,  PETRO, Roman ,  STRIZINEC, Miroslav

IPC: A61K9/20

Abstract: Stabilization of the pharmaceutical active solid substance atorvastatin alone or in a mixture with other solid substances embedded in a gaseous mixture is carried out in such a manner that in the surrounding gaseous mixture a partial pressure of oxygen of at most 2 kPa, preferably less than 1 kPa, more preferably less than 0.4 kPa is maintained. The corresponding partial pressure is achieved either by use of oxygen absorbers, by packaging under a pressure of 0.3 - 10 kPa, or by packaging under a slight overpressure of an inert gas, preferably nitrogen, the gas being introduced, by means of nozzles, into the cavities, optionally also into the space of the press roller and of the wiper station.

公开(公告)号：WO03032076A2

公开(公告)日：2003-04-17

申请号：PCT/CZ0200054

申请日：2002-10-10

Applicant: SVOBODA MARTIN ,  BOROVICKA JIRI ,  WEISER ANTONIN

Inventor： SVOBODA MARTIN ,  BOROVICKA JIRI ,  WEISER ANTONIN

IPC: B32B5/02 ,  B32B5/22 ,  B32B33/00 ,  D04H13/00 ,  G03B15/10 ,  B32B5/24

CPC classification number: D04H1/4374 ,  B32B5/02 ,  B32B5/22 ,  D04H13/00

Abstract: For film or TV industry , for a camouflage of a background by special effect shots taken in an interior or an exterior or for production of audiovisual or photographic works, there is designed a fabric comprising at least one optically effective textile layer having a thickness of 1 ,5 -12 mm, the layer consisting of a multiple of curved, poly-directionally oriented, in any plane linearly unaligned fibres having a thickness of 50 -200 mu m, provided the fibres occupy from 1 ,5 % up to 20 % of the textile layer volume while a space between the fibres occupies from 80 % up to 98,5 % of the said volume.

Abstract translation: 对于电影或电视行业来说，为了通过在内部或外部拍摄的特殊效果的照片伪造背景或用于制作视听或摄影作品，设计了一种织物，其包括至少一个具有厚度为1的光学有效织物层 ，5-12mm，该层由弯曲的多向定向的多个层组成，在任何平面中，线形不对准的纤维的厚度为50-200μm，条件是纤维占据了1.5％至20％ 纺织层体积，而纤维之间的空间占所述体积的80％至98.5％。

公开(公告)号：WO2008017278B1

公开(公告)日：2008-08-28

申请号：PCT/CZ2007000078

申请日：2007-08-09

Applicant: ZENTIVA AS ,  SVOBODA MARTIN ,  JAMPILEK JOSEF ,  KACIRKOVA MARTINA ,  TOMASEK VACLAV ,  LEHOCKY MIKULAS ,  HEJTMANKOVA LUDMILA ,  VOSATKA VACLAV

Inventor： SVOBODA MARTIN ,  JAMPILEK JOSEF ,  KACIRKOVA MARTINA ,  TOMASEK VACLAV ,  LEHOCKY MIKULAS ,  HEJTMANKOVA LUDMILA ,  VOSATKA VACLAV

IPC: C07C213/10 ,  A61K31/137 ,  C07C215/54

CPC classification number: C07C215/54 ,  C07C213/10

Abstract: A crystalline salt of 2-[(1R)-3-[bis(l-methylethyl)amino]-1-?henyl?ropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, wherein: a) at least 90 % of all crystals are present in a size smaller than 30 µm, b) at least 40 % of crystalline matter are smaller than 250 µm, c) the maximum size of crystals does not exceed 800 µm, d) the salt contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) provides a value lower than 0.1%. The method of its preparation involves at least one crystallization from water. A pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts further contains a filler, a disintegrant and a lubricant, said composition being free of ions of alkaline earth metals.

Abstract translation: 2 - [（1R）-3- [双（1-甲基乙基）氨基] -1-苯基乙酰基] -4-甲基 - 苯酚与（2R，3R）-2,3-二羟基丁二酸的结晶盐， 以名称R-tolterodine酒石酸盐，其中：a）至少90％的晶体以小于30μm的尺寸存在，b）至少40％的结晶物质小于250μm，c）最大尺寸 的晶体不超过800μm，d）盐含有小于0.1重量％的不需要的对映体S-托特罗定酒石酸酯，e）硫酸盐灰分析（Pharm.Eur。）的分析测试提供的值低于0.1％。 其制备方法涉及至少一种从水中的结晶。 含有托特罗定或其药学上可接受的盐的药物组合物还含有填料，崩解剂和润滑剂，所述组合物不含碱土金属的离子。

公开(公告)号：WO2008028685A1

公开(公告)日：2008-03-13

申请号：PCT/EP2007/007869

申请日：2007-09-10

Applicant: PAL INTERNATIONAL A.S. ,  PROCHÁZKA, Jaroslav ,  SVOBODA, Martin

Inventor： PROCHÁZKA, Jaroslav ,  SVOBODA, Martin

IPC: B60S1/04 ,  B60S1/34

CPC classification number: B60S1/3493 ,  B60S1/0488

Abstract: Bei einer Scheibenwischanlage an einem Kraftfahrzeug müssen die Enden der Wischerwellen gegenüber dem Aufprall eines Körpers nachgiebig ausgestaltet sein. Um dies zu verwirklichen, wird vorgeschlagen, die Scheibenwischerwellen (5) gegen eine Axialverschiebung in dem aufnehmenden Lagerteil (2) federnd zu sichern, wodurch eine Absorption der Stoßenergie insbesondere bei der Fußgängerkollision mit dem Fahrzeug möglich wird. Die federnde Sicherung umfasst erfindungsgemäß einen Haltering (4), der in einer radialen Nut (10) der Scheibenwischerwelle (5) eingesetzt ist, und an seinem Umfang durch ein federndes Sicherungsmittel (6) radial vorbelastet ist.

Abstract translation: 在机动车辆中的挡风玻璃雨刷系统，相对于所述刮水轴到身体的影响的端部必须被弹性地设计。 为了实现这一点，提出了防止轴向移动固定刮水器主轴（5）在接收轴承部件（2）弹性，从而吸收在特定的冲击能量在行人碰撞到车辆成为可能。 根据本发明的弹性固定包括被插入在所述擦拭器轴（5）的径向槽（10）的保持环（4），并在通过弹性固定装置（6）其周边被径向偏置。

公开(公告)号：WO2008017278A3

公开(公告)日：2008-07-10

申请号：PCT/CZ2007000078

申请日：2007-08-09

Applicant: ZENTIVA AS ,  SVOBODA MARTIN ,  JAMPILEK JOSEF ,  KACIRKOVA MARTINA ,  TOMASEK VACLAV ,  LEHOCKY MIKULAS ,  HEJTMANKOVA LUDMILA ,  VOSATKA VACLAV

Inventor： SVOBODA MARTIN ,  JAMPILEK JOSEF ,  KACIRKOVA MARTINA ,  TOMASEK VACLAV ,  LEHOCKY MIKULAS ,  HEJTMANKOVA LUDMILA ,  VOSATKA VACLAV

IPC: C07C213/10 ,  A61K31/137 ,  C07C215/54

CPC classification number: C07C215/54 ,  C07C213/10

Abstract: A crystalline salt of 2-[(1R)-3-[bis(l-methylethyl)amino]-1-?henyl?ropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, wherein: a) at least 90 % of all crystals are present in a size smaller than 30 µm, b) at least 40 % of crystalline matter are smaller than 250 µm, c) the maximum size of crystals does not exceed 800 µm, d) the salt contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) provides a value lower than 0.1%. The method of its preparation involves at least one crystallization from water. A pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts further contains a filler, a disintegrant and a lubricant, said composition being free of ions of alkaline earth metals.

Abstract translation: 2 - [（1R）-3- [双（1-甲基乙基）氨基] -1-苯基丙基] -4-甲基 - 苯酚与（2R，3R）-2,3-二羟基丁二酸的结晶盐， 以名称R-托特罗定酒石酸盐公知，其中：a）全部晶体的至少90％以小于30μm的尺寸存在，b）至少40％的晶体物质小于250μm，c）最大尺寸 的晶体不超过800μm，d）盐含有小于0.1重量％的不良对映体S-托特罗定酒石酸盐，e）硫酸盐灰分（欧洲药典）的分析测试提供的值低于0.1％。 其制备方法涉及至少一次从水中结晶。 含有托特罗定或其药学上可接受的盐的药物组合物还含有填充剂，崩解剂和润滑剂，所述组合物不含碱土金属离子。

公开(公告)号：WO2003032076A3

公开(公告)日：2003-04-17

申请号：PCT/CZ2002/000054

申请日：2002-10-10

Applicant: SVOBODA, Martin ,  BOROVIČKA, Jiří ,  WEISER, Antonín

Inventor： SVOBODA, Martin ,  BOROVIČKA, Jiří ,  WEISER, Antonín

IPC: G03B15/10

Abstract: For film or TV industry , for a camouflage of a background by special effect shots taken in an interior or an exterior or for production of audiovisual or photographic works, there is designed a fabric comprising at least one optically effective textile layer having a thickness of 1 ,5 -12 mm, the layer consisting of a multiple of curved, poly-directionally oriented, in any plane linearly unaligned fibres having a thickness of 50 -200 μm, provided the fibres occupy from 1 ,5 % up to 20 % of the textile layer volume while a space between the fibres occupies from 80 % up to 98,5 % of the said volume.

公开(公告)号：WO2005011638A2

公开(公告)日：2005-02-10

申请号：PCT/CZ2004000045

申请日：2004-08-05

Applicant: ZENTIVA AS ,  SEBEK PAVEL ,  PROKOPOVA ALENA ,  SVOBODA EDUARD ,  RADL STANISLAV ,  STACH JAN ,  SVOBODA MARTIN ,  KOVACIK ANDREJ ,  DANKO ADRIAN ,  PETRO ROMAN ,  STRIZINEC MIROSLAV

Inventor： SEBEK PAVEL ,  PROKOPOVA ALENA ,  SVOBODA EDUARD ,  RADL STANISLAV ,  STACH JAN ,  SVOBODA MARTIN ,  KOVACIK ANDREJ ,  DANKO ADRIAN ,  PETRO ROMAN ,  STRIZINEC MIROSLAV

IPC: A61K9/20 ,  A61K9/28 ,  A61K31/40

CPC classification number: A61K31/40 ,  A61K9/2054 ,  A61K9/2866

Abstract: Stabilization of the pharmaceutical active solid substance atorvastatin alone or in a mixture with other solid substances embedded in a gaseous mixture is carried out in such a manner that in the surrounding gaseous mixture a partial pressure of oxygen of at most 2 kPa, preferably less than 1 kPa, more preferably less than 0.4 kPa is maintained. The corresponding partial pressure is achieved either by use of oxygen absorbers, by packaging under a pressure of 0.3 - 10 kPa, or by packaging under a slight overpressure of an inert gas, preferably nitrogen, the gas being introduced, by means of nozzles, into the cavities, optionally also into the space of the press roller and of the wiper station.

Abstract translation: 药物活性固体物质阿托伐他汀单独或与包埋在气体混合物中的其它固体物质的混合物中的稳定化以这样的方式进行，即在周围的气体混合物中氧分压至多2kPa，优选小于1 kPa，更优选小于0.4kPa。 通过使用氧气吸收器，通过在0.3-10kPa的压力下包装，或者通过在稍微超压的惰性气体，优选氮气下包装来实现相应的分压，通过喷嘴将气体引入 腔体，可选地也进入压辊和擦拭器站的空间中。